ASTRAZENECA PLC DL-,25/ GB0009895292 /
10/2/2024 4:00:13 PM | Chg. +2.95 | Volume | Bid10/2/2024 | Ask10/2/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
143.90EUR | +2.09% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 222.49 bill.EUR | - | - |
GlobeNewswire
8/12
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
8/8
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
8/6
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6/26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
6/18
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/13
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
5/8
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
5/2
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...